Literature DB >> 3677300

Occurrence of circulating 7-deoxyaglycone metabolites of 4'-deoxydoxorubicin in man.

J Cummings1, D J Kerr, S B Kaye.   

Abstract

In five cancer patients we have determined the pharmacokinetics of 4'-deoxydoxorubicin (4'-DOX), its alcoholic metabolite 4'-deoxydoxorubicinol and the occurrence of circulating 7-deoxyaglycone metabolites. The 7-deoxyaglycone of the alcohol metabolite, the major aglycone of Adriamycin (ADR) present in man, was not detected in any serum sample. The 7-deoxyaglycone of the parent drug, which appears in concentrations in excess of 30 ng/ml after ADR administration, was detected in only 2/5 patients in trace amounts. These preliminary data indicate a difference in biotransformation between ADR and 4'-DOX despite their close structural similarities.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3677300     DOI: 10.1007/bf00570499

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  8 in total

1.  Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response.

Authors:  C E Myers; W P McGuire; R H Liss; I Ifrim; K Grotzinger; R C Young
Journal:  Science       Date:  1977-07-08       Impact factor: 47.728

Review 2.  Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.

Authors:  C W Young; V Raymond
Journal:  Cancer Treat Rep       Date:  1986-01

3.  Absence of generation of oxygen-containing free radicals with 4'-deoxydoxorubicin, a non-cardiotoxic anthracycline drug.

Authors:  A C Dickinson; J O DeJordy; M G Boutin; D Teres
Journal:  Biochem Biophys Res Commun       Date:  1984-12-14       Impact factor: 3.575

4.  Phase I and clinical pharmacological evaluation of 4'-deoxydoxorubicin in patients with advanced cancer.

Authors:  G F Stanton; V Raymond; R E Wittes; P Schulman; D Budman; R Baratz; L Williams; G R Petroni; N L Geller; C Hancock
Journal:  Cancer Res       Date:  1985-04       Impact factor: 12.701

5.  Metabolism of 4'-modified analogs of doxorubicin. unique glucuronidation pathway for 4'-epidoxorubicin.

Authors:  H Weenen; J M van Maanen; M M de Planque; J G McVie; H M Pinedo
Journal:  Eur J Cancer Clin Oncol       Date:  1984-07

6.  Marked inter-patient variation in adriamycin biotransformation to 7-deoxyaglycones: evidence from metabolites identified in serum.

Authors:  J Cummings; R Milstead; D Cunningham; S Kaye
Journal:  Eur J Cancer Clin Oncol       Date:  1986-08

7.  Method for the determination of 4'-deoxydoxorubicin, 4'-deoxydoxorubicinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography.

Authors:  J Cummings
Journal:  J Chromatogr       Date:  1985-06-14

8.  Comparative cardiotoxicity and antitumour activity of doxorubicin (adriamycin) and 4'-deoxydoxorubicin and the relationship to in vivo disposition and metabolism in the target tissues.

Authors:  J Cummings; N Willmott; I More; D J Kerr; J G Morrison; S B Kaye
Journal:  Biochem Pharmacol       Date:  1987-05-01       Impact factor: 5.858

  8 in total
  1 in total

1.  Use of human neuroblastoma continuous cell lines for in vitro drug sensitivity screening.

Authors:  B T Hill; R D Whelan; L K Hosking
Journal:  Invest New Drugs       Date:  1988-04       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.